BioCentury | Jun 22, 2020
Emerging Company Profile

Prosit Sole: chimeric proteins for rare disease

...over wild-type FGF18. Merck KGaA (Xetra:MRK) has completed Phase II testing of recombinant FGF18 sprifermin (AS902330...
BioCentury | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

...Other companies are also working on growth factor-based therapies to promote cartilage production. Merck KGaA’s Sprifermin...
BioCentury | Nov 9, 2017
Clinical News

Merck's sprifermin meets in Phase II for OA

...the Phase II FORWARD trial to treat osteoarthritis (OA) of the knee showing that sprifermin (AS902330...
...of 100 μg sprifermin every 6 or every 12 months. Compared to placebo, the higher sprifermin...
...a recombinant human fibroblast growth factor 18 (FGF18). Merck KGaA (Xetra:MRK), Darmstadt, Germany Product: Sprifermin (AS902330...
BioCentury | Nov 6, 2017
Clinical News

Merck's sprifermin passes Phase II test in OA

...from the Phase II FORWARD trial to treat osteoarthritis of the knee showing that sprifermin (AS902330...
...of 100 μg sprifermin every six or every 12 months. Compared to placebo, the higher sprifermin...
...authorities to determine next steps. Sprifermin is a recombinant human fibroblast growth factor 18 (FGF18). Allison Johnson AS902330 Sprifermin Merck...
BioCentury | Sep 24, 2012
Emerging Company Profile

Arcarios: Protecting chondrocytes

...KGaA 's Merck Serono S.A. unit also is pursuing disease-modifying therapeutics in OA. Merck Serono's sprifermin...
Items per page:
1 - 5 of 5